Physician profile
Ordessia Charran
NPI 1114345345
$1,155.82
in general payments reported to CMS, 2019-2025
13 companies · $99.99 in 2025
The $99.99 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10.94 · 2020: $314 · 2021: $525 · 2023: $64.40 · 2024: $141 · 2025: $99.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $205 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $205.41 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $302.72 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $270.48 | 2021-2024 | Tezspire |
| Philips North America LLC | $169.00 | 2020 | |
| Mylan Specialty L.P. | $115.84 | 2021 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $64.40 | 2023 | Uptravi, Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.32 | 2020-2021 | |
| Advanced Respiratory, INC | $21.77 | 2021 | |
| Zoll Respicardia, INC. | $19.25 | 2024 | Remede System |
| Harmony Biosciences LLC | $16.66 | 2021 | |
| United Therapeutics Corporation | $16.23 | 2021 | |
| La Jolla Pharmaceutical Company | $15.22 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ordessia Charran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.